Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)
Introduction Recent years have seen significant strides in drug developmenttargeting the
EGFR/RAS/RAF signaling pathway which is critical forcell growth and proliferation. Protein …
EGFR/RAS/RAF signaling pathway which is critical forcell growth and proliferation. Protein …
Transcriptomic FHITlow/pHER2high signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer
A Brisebarre, J Ancel, T Ponchel, E Loeffler… - Frontiers in …, 2022 - frontiersin.org
Introduction In recent decades, the development of immunotherapy and targeted therapies
has considerably improved the outcome of non-small cell lung cancer (NSCLC) patients …
has considerably improved the outcome of non-small cell lung cancer (NSCLC) patients …
Paired Comparison of Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using Three …
D Barthelemy, G Lescuyer, F Geiguer, E Grolleau… - Cancers, 2023 - mdpi.com
Simple Summary Circulating tumor DNA (ctDNA) samples reflect the total tumor burden and
allow longitudinal monitoring of mutational sensitizing alterations in routine use for …
allow longitudinal monitoring of mutational sensitizing alterations in routine use for …
[HTML][HTML] Structure-based classification of EGFR mutations in operable pre-invasive and invasive non-small cell lung cancer: a cross-sectional study
T Wang, J Cao, Q Song, L Wang, Y Xiong… - Journal of Thoracic …, 2022 - ncbi.nlm.nih.gov
Background It has been reported that the structure-based approach for defining functional
groups of epidermal growth factor receptor (EGFR) mutations predicts the efficacy of EGFR …
groups of epidermal growth factor receptor (EGFR) mutations predicts the efficacy of EGFR …
[PDF][PDF] Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer
I Barreto, S Figueiredo, FS Tonin, AS Vilariça… - Portuguese Journal of …, 2023 - pjctvs.com
10 disease [stage IVA (n= 8, 25.0%) or IVB (n= 13, 40.6%)]. Among patients diagnosed with
early stages (n= 11, 34.4%), all were submitted to surgery (n= 11, 100%). At the time of …
early stages (n= 11, 34.4%), all were submitted to surgery (n= 11, 100%). At the time of …